Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent

Dirk B. Mendel, A. Douglas Laird, Beverly D. Smolich, Robert A. Blake, Congxin Liang, Alison L. Hannah, Raymond M. Shaheen, Lee M. Ellis, Steve Weitman, Laura K. Shawver, Julie M. Cherrington

Research output: Contribution to journalReview article

272 Scopus citations

Abstract

Angiogenesis, or the sprouting of new blood vessels, is a central process in the growth of solid tumors. For many cancers, the extent of vascularization of a tumor is a negative prognostic indicator signifying aggressive disease and increased potential for metastasis. Recent efforts to understand the molecular basis of tumor-associated angiogenesis have identified several potential therapeutic targets, including the receptor tyrosine kinases for the angiogenic factor vascular endothelial growth factor (VEGF). Here we review the approach taken at SUGEN, Inc. to discover and develop small molecule inhibitors of receptor tyrosine kinases as anti-angiogenic agents. We focus on SU5416, a selective inhibitor of VEGF receptors that is currently in clinical development for the treatment of advanced malignancies. Its biochemical, biological and pharmacological properties are reviewed and clinical implications discussed.

Original languageEnglish (US)
Pages (from-to)29-41
Number of pages13
JournalAnti-Cancer Drug Design
Volume15
Issue number1
StatePublished - Feb 1 2000

Keywords

  • Angiogenesis
  • Cancer
  • Indolinones
  • SU5416

ASJC Scopus subject areas

  • Biochemistry
  • Oncology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Fingerprint Dive into the research topics of 'Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent'. Together they form a unique fingerprint.

Cite this